Stockreport

Singapore-based ImmunoScape Pioneers Next-Generation Cell Therapy for Solid Tumors; Announces Key Licensing Deal, New Board and SAB Appointments [Yahoo! Finance]

Cue Biopharma, Inc.  (CUE) 
US:NASDAQ Investor Relations: cuebiopharma.gcs-web.com/news-releases
PDF SINGAPORE, November 13, 2025 BUSINESS WIRE ImmunoScape Pte. Ltd. , an A*STAR spin out backed by Amgen Ventures and EDBi that is developing next-generation TCR-based can [Read more]